Replies to post #53588 on Regen BioPharma Inc (RGBP)

[trademax42]

O

n April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment in humans of
pancreatic cancer for a term of fifteen years from April 7, 2021.
The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.

https://www.otcmarkets.com/filing/conv_pdf?id=14860710&guid=156pUKMYSjzCAyh

whereby ONPH will gain access to Regen’s intellectual property “pertaining to mRNA to be used in developing a therapy for treating pancreatic cancer.”

https://investorplace.com/2021/04/rgbp-stock-why-little-known-regen-biopharma-is-soaring-800-today/?cc=quotes&cp=benzinga

$RGBP

Just my opinion as always.

[trademax42]

Look at this, 23 results:

https://patents.google.com/?inventor=David+Koos&sort=new

What we really like about the deals with Oncology Pharma is that Regen BioPharma is sitting on a very valuable patent portfolio. It was just a matter of time before they started monetizing it. Just doing a Google patent search yields 23 results.

https://insiderfinancial.com/regen-biopharma-about-to-become-a-major-pharma-player/181241/

$RGBP

Just my opinion as always.